Temporal trends in long-term survival and cure rates in esophageal cancer: a SEER database analysis - PubMed (original) (raw)
Temporal trends in long-term survival and cure rates in esophageal cancer: a SEER database analysis
Attila Dubecz et al. J Thorac Oncol. 2012 Feb.
Free article
Abstract
Purpose: To assess long-term temporal trends in population-based survival and cure rates in patients with esophageal cancer and compare them over the last 3 decades in the United States.
Methods: We identified 62,523 patients with cancer of the esophagus and the gastric cardia diagnosed between 1973 and 2007 from the Surveillance, Epidemiology, and End Results database. Long-term cancer-related survival and cure rates were calculated. Stage-by-stage disease-related survival curves of patients diagnosed in different decades were compared. Influence of available variables on survival and cure was analyzed with logistic regression.
Results: Ten-year survival was 14% in all patients. Disease-related survival of esophageal cancer improved significantly since 1973. Median survival in Surveillance, Epidemiology, and End Results stages in local, regional, and metastatic cancers improved from 11, 10, and 4 months in the 1970s to 35, 15, and 6 months after 2000. Early stage, age 45 to 65 years at diagnosis and undergoing surgical therapy were independent predictors of 10-year survival. Cure rate improved in all stages during the study period and were 73%, 37%, 12%, and 2% in stages 0, 1, 2, and 4, respectively, after the year 2000. Percentage of patients undergoing surgery improved from 55% in the 1970s to 64% between 2000 and 2007. Proportion of patients diagnosed with in situ and local cancer remains below 30%.
Conclusion: Long-term survival with esophageal cancer is poor but survival of local esophageal cancer improved dramatically over the decades. Complete cure of nonmetastatic esophageal cancer seems possible in a growing number of patients. Early diagnosis and treatment are crucial.
Similar articles
- Trends in esophageal cancer survival in United States adults from 1973 to 2009: A SEER database analysis.
Njei B, McCarty TR, Birk JW. Njei B, et al. J Gastroenterol Hepatol. 2016 Jun;31(6):1141-6. doi: 10.1111/jgh.13289. J Gastroenterol Hepatol. 2016. PMID: 26749521 Free PMC article. - Impact of prior malignancy on outcomes of stage IV esophageal carcinoma: SEER based study.
Saad AM, Al-Husseini MJ, Elgebaly A, Aboshady OA, Salahia S, Abdel-Rahman O. Saad AM, et al. Expert Rev Gastroenterol Hepatol. 2018 Apr;12(4):417-423. doi: 10.1080/17474124.2018.1426458. Epub 2018 Jan 16. Expert Rev Gastroenterol Hepatol. 2018. PMID: 29316808 - Trends in the incidence and survival of patients with esophageal cancer: A SEER database analysis.
He H, Chen N, Hou Y, Wang Z, Zhang Y, Zhang G, Fu J. He H, et al. Thorac Cancer. 2020 May;11(5):1121-1128. doi: 10.1111/1759-7714.13311. Epub 2020 Mar 10. Thorac Cancer. 2020. PMID: 32154652 Free PMC article. - Has combined modality therapy improved the outlook in carcinoma of the esophagus?
Philip PA, Ajani JA. Philip PA, et al. Oncology (Williston Park). 1994 Sep;8(9):37-42; discussion 44-5, 50-2, 61. Oncology (Williston Park). 1994. PMID: 7527642 Review. - Neoadjuvant chemoradiotherapy for esophageal cancer: is it worthwhile?
Tamim WZ, Davidson RS, Quinlan RM, O'Shea MA, Orr RK, Swanson RS. Tamim WZ, et al. Arch Surg. 1998 Jul;133(7):722-6. doi: 10.1001/archsurg.133.7.722. Arch Surg. 1998. PMID: 9687999 Review.
Cited by
- Trends in esophageal adenocarcinoma incidence and mortality.
Hur C, Miller M, Kong CY, Dowling EC, Nattinger KJ, Dunn M, Feuer EJ. Hur C, et al. Cancer. 2013 Mar 15;119(6):1149-58. doi: 10.1002/cncr.27834. Epub 2012 Dec 11. Cancer. 2013. PMID: 23303625 Free PMC article. - Conditional Survival of Patients Who Underwent Curative Resection for Esophageal Squamous Cell Carcinoma.
Shin DW, Kim HK, Cho J, Lee G, Cho J, Yoo JE, Shin S, Choi YS, Shim YM, Zo JI. Shin DW, et al. Ann Surg. 2022 Aug 1;276(2):e86-e92. doi: 10.1097/SLA.0000000000004473. Epub 2020 Oct 19. Ann Surg. 2022. PMID: 33086317 Free PMC article. - Age-specific risk factor profiles of adenocarcinomas of the esophagus: A pooled analysis from the international BEACON consortium.
Drahos J, Xiao Q, Risch HA, Freedman ND, Abnet CC, Anderson LA, Bernstein L, Brown L, Chow WH, Gammon MD, Kamangar F, Liao LM, Murray LJ, Ward MH, Ye W, Wu AH, Vaughan TL, Whiteman DC, Cook MB. Drahos J, et al. Int J Cancer. 2016 Jan 1;138(1):55-64. doi: 10.1002/ijc.29688. Epub 2015 Aug 26. Int J Cancer. 2016. PMID: 26175109 Free PMC article. - The role of radiation therapy in resected T2 N0 esophageal cancer: a population-based analysis.
Martin JT, Worni M, Zwischenberger JB, Gloor B, Pietrobon R, D'Amico TA, Berry MF. Martin JT, et al. Ann Thorac Surg. 2013 Feb;95(2):453-8. doi: 10.1016/j.athoracsur.2012.08.049. Epub 2012 Oct 11. Ann Thorac Surg. 2013. PMID: 23063200 Free PMC article. - Ex vivo drug sensitivity testing as a means for drug repurposing in esophageal adenocarcinoma.
Lohse I, Al-Ali H, Volmar CH, D Alvarez Trotta A, Brothers SP, Capobianco AJ, Wahlestedt C. Lohse I, et al. PLoS One. 2018 Sep 13;13(9):e0203173. doi: 10.1371/journal.pone.0203173. eCollection 2018. PLoS One. 2018. PMID: 30212533 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical